TransMedics' stock remains under pressure after a weak third quarter, reduced Q4 guidance, the exit of the company's CFO, and ...

The crucial limitation in paediatric cardiac donation in DCD has been technological, as the currently approved ex situ mechanical perfusion device (TransMedics OCS Heart ... child DCD heart recovery.

TransMedics Group (NASDAQ:TMDX), Inc., a Massachusetts-based medical technology company with a market capitalization of $2.1 billion, has completed the acquisition of a fleet of aircraft aimed at ...

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of TransMedics Group, Inc. (“TransMedics” or ...

paints a grim picture of TransMedics’ business practices. The report’s allegations center on the company’s warm perfusion technology platform, known as the Organ Care System (OCS), and its ...

NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of TransMedics Group ...

About TransMedics Group, Inc. TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment ... on the success of the Organ Care System or OCS; our ability to expand ...

Scorpion Capital announced plans to file a Citizen Petition with the FDA, requesting the suspension of Premarket Approval (PMA) for TransMedics’ Organ Care System (OCS). The short seller also ...

GOTHENBURG, SWEDEN / ACCESSWIRE / January 13, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) Invitation to attend XVIVO's conference call regarding the presentation of the Year-end ...